Clinical Trial Update: Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and potential efficacy of combining blinatumomab with nivolumab, with or without ipilimumab, in patients with poor-risk re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Mixed Phenotype Acute Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-16